CN104321048B - 抑制神经元胞吐的化合物(ii) - Google Patents

抑制神经元胞吐的化合物(ii) Download PDF

Info

Publication number
CN104321048B
CN104321048B CN201380026300.0A CN201380026300A CN104321048B CN 104321048 B CN104321048 B CN 104321048B CN 201380026300 A CN201380026300 A CN 201380026300A CN 104321048 B CN104321048 B CN 104321048B
Authority
CN
China
Prior art keywords
seq
group
agent
following formation
reagent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380026300.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN104321048A (zh
Inventor
A·菲尔勒蒙蒂埃尔
G·费尔南德兹巴勒斯特尔
J·M·加西亚安东
C·卡雷诺塞尔莱马
N·阿尔米尼亚纳多梅内奇
R·德尔加多冈萨雷斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lubrizol Advanced Materials Inc
Original Assignee
Lubrizol Advanced Materials Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP12382144.9A external-priority patent/EP2649983A1/de
Application filed by Lubrizol Advanced Materials Inc filed Critical Lubrizol Advanced Materials Inc
Publication of CN104321048A publication Critical patent/CN104321048A/zh
Application granted granted Critical
Publication of CN104321048B publication Critical patent/CN104321048B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/11—Encapsulated compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201380026300.0A 2012-04-13 2013-04-12 抑制神经元胞吐的化合物(ii) Active CN104321048B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP12382144.9A EP2649983A1 (de) 2012-04-13 2012-04-13 Verbindungen zur Hemmung neuronaler Exozytose (II)
EP12382144.9 2012-04-13
US201261652647P 2012-05-29 2012-05-29
US61/652,647 2012-05-29
EP12382303 2012-07-27
EP12382303.1 2012-07-27
US201261746888P 2012-12-28 2012-12-28
US61/746,888 2012-12-28
PCT/EP2013/057656 WO2013153191A1 (en) 2012-04-13 2013-04-12 Compounds which inhibit neuronal exocytosis (ii)

Publications (2)

Publication Number Publication Date
CN104321048A CN104321048A (zh) 2015-01-28
CN104321048B true CN104321048B (zh) 2019-01-11

Family

ID=49327143

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380026300.0A Active CN104321048B (zh) 2012-04-13 2013-04-12 抑制神经元胞吐的化合物(ii)

Country Status (11)

Country Link
US (1) US10035820B2 (de)
EP (1) EP2836193B1 (de)
JP (1) JP6470678B2 (de)
KR (1) KR102113994B1 (de)
CN (1) CN104321048B (de)
AU (1) AU2013246882B2 (de)
BR (1) BR112014025396B1 (de)
CA (1) CA2869599C (de)
ES (1) ES2660901T3 (de)
MX (1) MX356343B (de)
WO (1) WO2013153191A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016063805A1 (ja) * 2014-10-21 2016-04-28 日産化学工業株式会社 レジスト下層膜形成組成物
CN109414417A (zh) * 2016-03-17 2019-03-01 约翰·霍普金斯大学 通过paris的法尼基化预防或治疗帕金森症的方法
US10154958B1 (en) 2017-07-20 2018-12-18 King Abdulaziz University Composition containing essential oils and plant extracts for treating vaginal infection and inflammation
JP2021528390A (ja) * 2018-06-13 2021-10-21 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニＡｚｉｅｎｄｅ Ｃｈｉｍｉｃｈｅ Ｒｉｕｎｉｔｅ Ａｎｇｅｌｉｎｉ Ｆｒａｎｃｅｓｃｏ Ａ．Ｃ．Ｒ．Ａ．Ｆ．Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ ムスカリン受容体ｍ３に対して阻害活性を有するペプチド
EP3906013A1 (de) 2019-01-02 2021-11-10 The Procter & Gamble Company Hautpflegezusammensetzung mit peptidverbindung und exopolysaccharid-extrakt aus aphanothece sacrum
AU2020277930B2 (en) * 2019-05-21 2024-06-13 Eyebio Korea Novel peptide compound or pharmaceutically acceptable salt thereof
CN111345293B (zh) * 2020-04-08 2021-08-27 江门海关技术中心 一种虫类标本用防蛀剂及其制备方法
KR102584000B1 (ko) 2021-01-19 2023-10-06 김기연 신경전달물질을 조절하는 펩타이드를 포함하는 스포츠 로션 조성물
US11571378B2 (en) 2021-01-22 2023-02-07 The Procter & Gamble Company Skin care composition and method of using the same
US11771637B2 (en) 2021-01-22 2023-10-03 The Procter & Gamble Company Skin care composition and method of using the same
WO2023161264A1 (en) * 2022-02-23 2023-08-31 Prospera Biotech, S.L. Compositions for treating hyperhidrosis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050611A1 (en) * 2004-11-12 2006-05-18 The University Of British Columbia Antimicrobial peptides
CN101541831A (zh) * 2006-10-25 2009-09-23 利普泰股份公司 神经元胞吐抑制性肽类
WO2011009626A1 (en) * 2009-07-24 2011-01-27 Lipotec, S.A. Compounds which inhibit muscle contraction
KR101046426B1 (ko) * 2010-06-25 2011-07-04 주식회사 에코덤 항균 펩타이드 및 이를 포함하는 항균 조성물

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6939852B2 (en) 1991-09-24 2005-09-06 Allergan, Inc. Methods and compositions for the treatment of cerebral palsy
EP1099445A3 (de) 1993-06-10 2001-09-05 Allergan, Inc. Behandlung neuromuskulärer Erkrankungen und Zuständen mit unterschiedlichen Botulinum Serotypen
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
DK0758900T3 (da) 1994-05-09 2002-07-29 William J Binder Botulinumtoksin til reduktion af migræne-hovedpinesmerter
WO1997034620A1 (en) 1996-03-18 1997-09-25 The Regents Of The University Of California Peptide inhibitors of neurotransmitter secretion by neuronal cells
US7807182B2 (en) * 1996-12-31 2010-10-05 Colorado State University Research Foundation Early detection of mycobacterial disease using peptides
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
ES2160485B1 (es) 1999-04-23 2002-05-16 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
WO2001018038A2 (en) * 1999-08-20 2001-03-15 Imperial College Innovations Limited Isoforms of snare molecules and the uses thereof in modulation of cellular exocytosis
US6358917B1 (en) 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
EP2275552B1 (de) * 1999-10-29 2015-09-09 GlaxoSmithKline Biologicals SA Antigenpeptide aius Neisseria
US7838007B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6500436B2 (en) 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6641820B1 (en) 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US6524580B1 (en) 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6319506B1 (en) 2000-02-22 2001-11-20 Allergan, Sales, Inc. Method for treating hypercalcemia
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6565870B1 (en) 2000-04-28 2003-05-20 Allergan, Inc. Methods for treating bone tumors
US6306403B1 (en) 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US6831059B2 (en) 2000-10-20 2004-12-14 Allergan, Inc. Compositions and methods for treating gonadotrophin related illnesses
US7255865B2 (en) 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
US7208279B2 (en) * 2001-03-14 2007-04-24 Caden Biosciences, Inc. Method for identifying inhibitors of G protein coupled receptor signaling
ATE406910T1 (de) 2001-07-27 2008-09-15 Univ Louisiana State Botulinustoxin bei der behandlung und prävention von akne
US7255866B2 (en) 2001-09-17 2007-08-14 Allergan, Inc. Botulinum toxin therapy for fibromyalgia
US6623742B2 (en) 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
WO2003073994A2 (en) 2002-03-01 2003-09-12 Elan Pharmaceuticals, Inc. Methods of treating nerve entrapment syndromes
US6921538B2 (en) 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US6776991B2 (en) 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US7238357B2 (en) 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
US7393537B2 (en) 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US6838434B2 (en) 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US7220422B2 (en) 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US8871224B2 (en) 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US8048423B2 (en) 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US7270287B2 (en) 2004-01-06 2007-09-18 Allergan, Inc. Botulinum toxin treatment for kinesia
US20050191321A1 (en) 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
ES2555856T3 (es) 2004-09-23 2016-01-11 Toxcure, Inc. Tratamiento de neoplasmas con neurotoxina
SG160358A1 (en) 2005-03-03 2010-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of an oligopeptide
US7811586B2 (en) 2006-05-02 2010-10-12 Allergan, Inc. Methods for alleviating testicular pain
US7846457B2 (en) 2006-05-04 2010-12-07 Steinsapir Kenneth D Cosmetic use of botulinum toxin for the treatment of eyebrow and forehead ptosis, and unwanted eyebrow expression
WO2008026852A1 (en) * 2006-08-31 2008-03-06 Forhumantech Co., Ltd. Fusion polypeptide for inhibiting neurotransmitter secretion and method for delivering it
KR20090041066A (ko) * 2007-10-23 2009-04-28 성균관대학교산학협력단 신경전달물질 배출을 조절하는 합성 펩타이드
JP5538359B2 (ja) 2008-04-04 2014-07-02 リペラ ファーマシューティカルズ， インコーポレイテッド リポソームボツリヌス毒素を使用する膀胱機能障害の治療
ES2356883B1 (es) 2008-07-24 2012-02-22 Bcn Peptides, S.A. Composición para el tratamiento del dolor y/o la inflamación.
US20100028385A1 (en) 2008-08-04 2010-02-04 Allergan, Inc. Treatment of excess cerumen secretion
PT2413947T (pt) 2009-04-01 2020-05-28 Revance Therapeutics Inc Métodos e composições para tratar condições de pele associadas à hiper-reatividade vascular
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
CA2774951C (en) 2009-09-24 2014-12-16 Allergan, Inc. Method of treating osteoporosis with a neurotoxin
WO2011048443A1 (en) 2009-10-20 2011-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Neuronal exocytosis inhibiting peptides derived from c subunit of v-atpase and cosmetic and pharmaceutical compositions containing said peptides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050611A1 (en) * 2004-11-12 2006-05-18 The University Of British Columbia Antimicrobial peptides
CN101541831A (zh) * 2006-10-25 2009-09-23 利普泰股份公司 神经元胞吐抑制性肽类
WO2011009626A1 (en) * 2009-07-24 2011-01-27 Lipotec, S.A. Compounds which inhibit muscle contraction
KR101046426B1 (ko) * 2010-06-25 2011-07-04 주식회사 에코덤 항균 펩타이드 및 이를 포함하는 항균 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A synthetic hexapeptide (Argireline) with antiwrinkle activity;C. Blanes-Mira等;《International Journal of Cosmetic Science》;20021231;第24卷(第5期);303-310
Identification of SNARE complex modulators that inhibit exocytosis from an α-helix-constrained combinatorial library;Clara BLANES-MIRA等;《BIOCHEMICAL JOURNAL》;20031231;第375卷;159-166

Also Published As

Publication number Publication date
KR102113994B1 (ko) 2020-05-25
EP2836193A1 (de) 2015-02-18
CN104321048A (zh) 2015-01-28
BR112014025396B1 (pt) 2020-03-17
ES2660901T3 (es) 2018-03-26
WO2013153191A1 (en) 2013-10-17
CA2869599C (en) 2021-07-27
EP2836193B1 (de) 2018-01-31
US20150098989A1 (en) 2015-04-09
KR20150002800A (ko) 2015-01-07
MX2014012223A (es) 2014-11-25
JP6470678B2 (ja) 2019-02-13
US10035820B2 (en) 2018-07-31
MX356343B (es) 2018-05-23
CA2869599A1 (en) 2013-10-17
JP2015514124A (ja) 2015-05-18
AU2013246882A1 (en) 2014-10-09
AU2013246882B2 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
CN104321048B (zh) 抑制神经元胞吐的化合物(ii)
CN102470160B (zh) 抑制肌肉收缩的化合物
CN110003310A (zh) 抑制神经元胞吐的化合物(iii)
CN104321049B (zh) 抑制神经元胞吐的化合物
EP2649983A1 (de) Verbindungen zur Hemmung neuronaler Exozytose (II)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant